Purpose: The aim of this study was to evaluate the efficacy and safety of combination treatment using surgical reduction technique and 532-nm Q-switched Nd:YAG laser treatment for the removal of oculodermal melanocytosis.
Methods: We retrospectively reviewed the medical records of patients who underwent combination treatment using surgical reduction and 532-nm Q-switched Nd:YAG laser for the removal of ocular pigmentation in oculodermal melanocytosis at Asan Medical Center (Seoul, Korea) between January 2009 and January 2013. The safety and cosmetic efficacy of this new surgical strategy were assessed by both patients and observers.
Results: Fifty eyes of 47 patients with oculodermal melanocytosis were enrolled. Ocular pigmentation was successfully reduced in all patients, and all patients were satisfied with the cosmetic results at the last visit. Preoperative and postoperative corrected visual acuity, keratometry, and refractive errors did not significantly differ. Postoperative intraocular pressure was significantly reduced (mean change, 2.33 ± 3.54 mm Hg; P = 0.03) at 1 month after surgery. During the follow-up period, no serious adverse events developed other than conjunctival neovascularization and conjunctival inclusion cyst in 5 eyes, respectively.
Conclusions: Combination treatment for oculodermal melanocytosis removal seems to be cosmetically satisfactory and safe. This study suggested that combination treatment using surgical technique and 532-nm Q-switched Nd:YAG laser may be helpful for the removal of oculodermal melanocytosis.
*Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; and
†Research Institute for Biomacromolecules, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Reprints: Hungwon Tchah, MD, PhD, Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea (e-mail: email@example.com).
The authors have no funding or conflicts of interest to disclose.
Received March 15, 2014
Accepted April 15, 2014